Product Name :
LHF-535
Description:
LHF-535 is an antiviral agent extracted from patent WO2013123215A2, Compound 38, has EC50s of <1 μM, <1 μM, <1 μM, and 1-10 μM for Lassa, Machupo, Junin, and VSVg virus, respectively.
CAS:
1450929-77-7
Molecular Weight:
412.52
Formula:
C27H28N2O2
Chemical Name:
2-{4-[(Z)-2-{1-[4-(propan-2-yloxy)phenyl]-1H-1,3-benzodiazol-5-yl}ethenyl]phenyl}propan-2-ol
Smiles :
CC(C)OC1C=CC(=CC=1)N1C=NC2=CC(/C=C\C3C=CC(=CC=3)C(C)(C)O)=CC=C12
InChiKey:
DBNZTRPIBJSUIX-WAYWQWQTSA-N
InChi :
InChI=1S/C27H28N2O2/c1-19(2)31-24-14-12-23(13-15-24)29-18-28-25-17-21(9-16-26(25)29)6-5-20-7-10-22(11-8-20)27(3,4)30/h5-19,30H,1-4H3/b6-5-
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
LHF-535 is an antiviral agent extracted from patent WO2013123215A2, Compound 38, has EC50s of Product information|CAS Number: 1450929-77-7|Molecular Weight: 412.{{Substance P} medchemexpress|{Substance P} Neuronal Signaling|{Substance P} Purity & Documentation|{Substance P} In stock|{Substance P} manufacturer|{Substance P} Epigenetics} 52|Formula: C27H28N2O2|Chemical Name: 2-{4-[(Z)-2-{1-[4-(propan-2-yloxy)phenyl]-1H-1,3-benzodiazol-5-yl}ethenyl]phenyl}propan-2-ol|Smiles: CC(C)OC1C=CC(=CC=1)N1C=NC2=CC(/C=C\C3C=CC(=CC=3)C(C)(C)O)=CC=C12|InChiKey: DBNZTRPIBJSUIX-WAYWQWQTSA-N|InChi: InChI=1S/C27H28N2O2/c1-19(2)31-24-14-12-23(13-15-24)29-18-28-25-17-21(9-16-26(25)29)6-5-20-7-10-22(11-8-20)27(3,4)30/h5-19,30H,1-4H3/b6-5-|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : 96.{{Atenolol} medchemexpress|{Atenolol} GPCR/G Protein|{Atenolol} Biological Activity|{Atenolol} In Vivo|{Atenolol} supplier|{Atenolol} Cancer} 67 mg/mL (234.PMID:23907521 34 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|LHF-535 is a small-molecule viral entry inhibitor that targets the arenavirus envelope glycoprotein (GP). LHF-535 exhibits potent antiviral activity against a broad array of hemorrhagic fever arenaviruses. LHF-535 inhibits Lassa GP-pseudotyped lentivirus with an IC50 of 0.1-0.3 nM.|In Vivo:|LHF-535 (3, 10 or 30 mg/kg; orally; daily; 14 days) protectes mice from a lethal challenge with Tacaribe virus and dramatically reduces viral titers in plasma, spleen, and liver. An increase in survival is also observed when the first dose of LHF-535 (10 mg/kg) is delayed by 1, 2, or 3 days after infection, demonstrating that LHF-535 is efficacious as a post-exposure therapeutic in mice.|Products are for research use only. Not for human use.|